AN2 Therapeutics, Inc. — Net Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/8345bf8a-5eed-4a00-9fc9-498f615d0c89/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-35.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-110693 |
| FY 2024 | $-51.3M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-044366 |
| FY 2023 | $-64.7M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-038681 |
| FY 2022 | $-41.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-010627 |
| FY 2021 | $-21.5M | 2021-01-01 – 2021-12-31 | evidence 0000950170-23-010627 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).